Hofseth Biocare ASA

Hofseth Biocare ASA

0.12
USD
-0.05
(-28.99%)
-0.03EPS

Share Statistics

As of September 30, 2026, HOFSETH BIOCARE AS has 506.23M shares outstanding.

Shares Outstanding506.23M

Financial Position

As of September 30, 2026, HOFSETH BIOCARE AS maintains a current ratio of 0.96, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -11,441.34, indicating conservative leverage, while an interest coverage ratio of -1.40 demonstrates limited ability to service its debt obligations.

Current Ratio0.96
Quick Ratio0.22
Debt / Equity-11,441.34
Debt / EBITDA-5.89
Interest Coverage-1.40

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -32.25, reflecting losses generated across the asset base. The company generates approximately 335,535.52 in revenue per employee across its workforce of 84.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.32 indicates how many times HOFSETH BIOCARE AS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-32.25
Revenue Per Employee335,535.52
Employee Count84.00
Inventory Turnover2.32

Taxes

USD

Over the twelve months ended September 30, 2026, HOFSETH BIOCARE AS recorded 18,943.83 in income tax expense. The company reported a pretax loss of -12.59M and -12.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax18,943.83

Stock Price Statistics

USD

As of the close on October 26, 2026, HOFSETH BIOCARE AS's stock has declined approximately 28.99% over the past 52 weeks.

52-Week Price Change-28.99%
50-Day Moving Average0.71

Income Statement

USD

Over the twelve months ended September 30, 2026, HOFSETH BIOCARE AS generated 28.18M in revenue and converted that into -12.61M in net income, yielding earnings per share of -0.03. EBITDA reached -4.99M, while operating income came in at -9.32M.

Revenue28.18M
Gross Profit12.26M
Operating Income-9.32M
Pretax Income-12.59M
Net Income-12.61M
EBITDA-4.99M
EBIT-9.32M
Earnings Per Share (EPS)-0.03

Balance Sheet

USD

As of September 30, 2026, HOFSETH BIOCARE AS holds 3.50M in cash and equivalents against 29.36M in total debt, resulting in a net debt position of 18.11M. Total book value stands at -184,754.38, with working capital of -709,456.82 providing operational flexibility.

Cash & Cash Equivalents3.50M
Total Debt29.36M
Net Debt18.11M
Equity (Book Value)-184,754.38
Working Capital-709,456.82

Cash Flow

USD

HOFSETH BIOCARE AS produced -4.37M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -3.16M in capital expenditures, free cash flow totaled -7.52M - equivalent to -0.02 per share.

Operating Cash Flow-4.37M
Capital Expenditures-3.16M
Free Cash Flow-7.52M
FCF Per Share-0.02

Margins

Over the twelve months ended September 30, 2026, HOFSETH BIOCARE AS posted a gross margin of 43.50, reflecting its pricing power and cost economics. The operating margin of -33.07 and net profit margin of -44.73 provide insight into operational efficiency.

Gross Margin43.50
Operating Margin-33.07
Pretax Margin-44.66
Profit Margin-44.73
EBITDA Margin-17.69

Stock Splits

HOFSETH BIOCARE AS's most recent stock split took place on October 16, 2020.

Last Split Date10/16/2020